Cure8 research brief
A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.
Clinicians who manage UC, researchers studying IBD biomarkers, and adults with ulcerative colitis interested in noninvasive monitoring
Researchers retrospectively analyzed 182 UC patients who had blood and stool tests within 14 days of colonoscopy. SAA correlated strongly with other inflammatory markers (LRG and CRP) and with endoscopic disease severity scores.
The authors report cutoffs for SAA that identified active endoscopic inflammation (MES ≥2) and that distinguished complete endoscopic remission (MES 0) from mild residual inflammation (MES 1).
How this might be used: If validated prospectively, SAA could become another noninvasive blood test to help judge mucosal healing and guide the need for endoscopy or treatment adjustments. Current results come from a single retrospective cohort.
This report is a retrospective single-center analysis (182 patients) using colonoscopy as the reference standard; prospective validation in independent cohorts is needed before SAA could be adopted in routine practice. The structured content is based on the article abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
